Benign Paroxysmal Positional Vertigo | BPPV Treatment in Biaxial Rotational Chair
Benign Paroxysmal Positional Vertigo research study
What is the primary objective of this study?
Benign paroxysmal positional vertigo (BPPV) represents the most common cause of labyrinthine vertigo with a lifetime prevalence of 2.4 percent. Onset is most common between the fifth and seventh decades of life. The disease can be a major handicap for the affected patient, and causes a great expense for society. The traditional manual treatment with repositioning maneuvers has greatly improved the possibilities for treatment of BPPV the last decade. However some patients are still difficult to diagnose and treat, and there are some who for health reasons cannot undergo traditional manual treatment. In this perspective there is a demand for a reliable, effective and precise method to treat all semicircular canals for the differentiated patient groups, and the techniques are under continuous development.
Who is eligible to participate?
Inclusion Criteria: - subjects over 18 years with benign paroxysmal positional vertigo(BPPV) Exclusion Criteria: - BPPV previously treated with reposition maneuvers within the last 12 months. - Cochlear Implant (CI). - Asymmetrical hearing loss. - Unusual headache. - Neurological disease. - Inner ear disease other than BPPV. - Semicircular canal paresis. - Drug that causes dizziness/nystagmus. - Chemotherapy. - Hospital admission due to head trauma within the last 12 months. - Closeness to study group. - Downbeating nystagmus or upbeating nystagmus without torsional component. - Extensive spontaneous nystagmus that complicates gait interpretation. - Cannot tolerate both treatments. - Pregnancy. - Bilateral affection of the semicircular canals. - More than two semicircular canals affected on one side.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Benign Paroxysmal Positional Vertigo
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Device:Biaxial rotational chairThis chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Nystagmus in normal populationInvestigate positional nystagmus in normal population using a biaxial rotational chair.
BPPV treatment in TRV chairBPPV treatment in Biaxial rotational chair, describe and measure efficacy of treatment.
Barbecue treatment without accelerationTreatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient is positioned in supine position and rotated 30 degrees stepwise towards the unaffected ear, thus applying an overall 360 degrees rotation. The patient remains in each position for 30 seconds
Barbecue treatment with acceleartionTreatment of horizontal BPPV with adapted maneuvers using a biaxial rotational chair and infrared videoscopy goggle. The patient starts in supine position and will be rotated about a horizontal axis from head to feet. The patient will be rotated 360 degrees with a succession of eight fast rounds in the axial plane towards the unaffected side.
Start Date: August 2013
Completed Date: July 2017
Primary Outcome: Treatment of lateral semicircular BPPV, a randomized study comparing dynamic "barbecue" (D-BBC) (rotation about a horizontal axis from head to feet from a supine position) to stepwise barbecue (S-BBC) treatment in a biaxial rotational chair.
Secondary Outcome: Incidence and treatment of BPPV in a biaxial rotational chair (TRV chair).
Study sponsors, principal investigator, and references
Principal Investigator: Camilla Martens, MD
Lead Sponsor: Haukeland University Hospital